Down 81% since going public, could this iconic FTSE 250 company be a January bargain?

Oliver Rodzianko takes a look at Dr. Martens from the FTSE 250 to see if this could be an opportune time for him to buy some of its shares.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young Caucasian woman with pink her studying from her laptop screen

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing in shares that are down over 80% can seem daunting. After all, some companies’ share prices fall for good reason. Yet, I think this FTSE 250 business might be an opportunity.

Most people know Dr. Martens (LSE:DOCS) well. It’s become iconic in London, and the brand has spread around the world for its fashionable footwear.

The company has had rich cultural significance since the 1960s. It also initiated a successful turnaround culminating in 2010. But are the shares really worth me owning today?

Doc Martens in 2024

This year, the management is focusing on driving sustainable profitability and growth, focusing on shareholder value.

It currently has a strategy called DOCS, focused on direct-to-customer sales, operational excellence, customer connections, and supporting business-to-business partnerships.

The company now operates in three primary regions: Europe, Middle East, and Africa (EMEA); the Americas; and Asia Pacific (APAC).

It sells products from various segments, including Originals, Fusion, Kids, and Casual ranges.

A closer look at the financials

The firm has reported growing revenues and earnings since its initial public offering (IPO) in 2021. However, there’s been significant volatility in the results, particularly for its earnings per share:


Source: TradingView

While the above graph paints a turbulent financial picture for Dr. Martens in the last few years, generally the company’s growth is good.

After all, the firm’s three-year average annual revenue growth rate is over 14%.

Also, the company’s price-to-earnings (P/E) ratio stands at around eight, particularly cheap compared to past prices. It’s also strong for its sector, considering an industry median of around 19.


Source: TradingView

While the above points look relatively promising to me, the organisation’s balance sheet does present some cause for concern.

As of its last annual report in March, it had £446m in debt and only £158m in cash on its books.

While that’s not terrible, it has gotten worse, and taking into account the trailing 12-month period, it has £530m in debt and £46m in cash. If the company faces economic hardships, it might need to raise more finances to pay its debts.

Other risks I’m considering

As of 26 January 2024, the Dr. Marten’s share price had dropped 39% in a year. While the company faced a significant drop in revenue during the period, it did maintain its trading expectations.

To me, that means such a steep decline in the share price was slightly unwarranted. However, it outlines a risk of volatility for Dr. Marten’s shareholders.

Also, while inflation and interest rates are expected to ease soon, there’s no guarantee of this, and any wider economic setbacks could contribute to reduced consumer spending over some time. Therefore, I think the shares might have slower or even negative growth in the near future.

It’s on my watchlist

I’m taking my time before adding these value shares to my portfolio.

As I’ve learned from Warren Buffett: I don’t need to pick many great investments in my lifetime to end up rich. It’s the quality of the ones I choose that really matters. Deciding on that often takes time.

If I do invest, I’ll be giving it at least five years to start seeing the investment returns I’d like. That’s not something I mind, as I like to buy investments with the intention of holding them for at least a decade.

Oliver Rodzianko has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the S&P 500 crash in 2026?

The S&P 500 delivered impressive gains in 2025, but valuations are now running high. Are US stocks stretched to breaking…

Read more »

Teenage boy is walking back from the shop with his grandparent. He is carrying the shopping bag and they are linking arms.
Investing Articles

How much do you need in a SIPP to generate a brilliant second income of £2,000 a month?

Harvey Jones crunches the numbers to show how investors can generate a high and rising passive income from a portfolio…

Read more »

Investing Articles

Will Lloyds shares rise 76% again in 2026?

What needs to go right for Lloyds shares to post another 76% rise? Our Foolish author dives into what might…

Read more »

Investing Articles

How much passive income will I get from investing £10,000 in an ISA for 10 years?

Harvey Jones shows how he plans to boost the amount of passive income he gets when he retires, from FTSE…

Read more »

Investing Articles

Down 34% in 2025 — but could this be one of the UK’s top growth stocks for 2026?

With clarity over research funding on the horizon, could Judges Scientific be one of the UK’s best growth stocks to…

Read more »

piggy bank, searching with binoculars
Investing Articles

Can the rampant Barclays share price beat Lloyds in 2026?

Harvey Jones says the Barclays share price was neck and neck with Lloyds over the last year, and checks out…

Read more »

Investing Articles

Here’s how Rolls-Royce shares could hit £25 in 2026

If Rolls-Royce shares continue their recent performance, then £25 might be on the cards for 2026. Let's take a look…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

Prediction: in 2026 the red-hot Rolls-Royce share price could turn £10,000 into…

Harvey Jones can't believe how rapidlly the Rolls-Royce share price has climbed. Now he looks at the FTSE 100 growth…

Read more »